Atypical antipsychotics in improvement of Quality of life in Bipolar disorder - POLE

Study identifier:NIS-NKR-SER-2008/1

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A 8-week, Multicenter, Open-label, Observational Study of Atypical antipsychotics in improvement of quality of life in Bipolar disorder

Medical condition

Naturalistic

Phase

Healthy volunteers

Study drug

Sex

All

Actual Enrollment

1000

Study type

Observational

Age

18 Years - 65 Years

Date

Study Start Date: 01 Jul 2008

Primary Completion Date: 01 Nov 2008

Study Completion Date: 01 Nov 2008

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

Location

Research Site

Kyunggi-do, Choonchun-si, Republic of Korea

Location

RFesearch Site

Dae-gu, Joong-gu, Republic of Korea

Arms	Assigned Interventions

"There is no result for the study"

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=944&filename=CSR-NIS-NKR-SER-2008-1.pdf
Download
CSR-NIS-NKR-SER-2008-1.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

Korea Clinical Study Information

0082-2-2188-2145

yookyung.kim@astrazeneca.com

Investigators

Principal Investigator

Joon-Woo Bahn

Astrazeneca, Korea